|
Paul S. Berry (born September 24, 1957) is a noted investigator of HIV. He graduated from The George Washington University with a medical degree. He has a MBA from UC Irvine and a Juris Doctorate Degree from UC Berkeley Boalt Hall. He created the model used for HIV clinical research done in the setting of primary care physician's offices. In conjunction with Roche Molecular Systems, he pioneered the commercialization of HIV-1 viral quantification via Amplicor. He performed the viral load testing for Merck data submission to the U.S. Food and Drug Administration for approval of Crixivan. Dr. Berry served as principal investigator〔http://www.journals.uchicago.edu/CID/journal/issues/v37n8/30941/30941.web.pdf〕〔http://www.aidsinfobbs.org/periodicals/search/33〕〔http://www.qrd.org/qrd/aids/atn/1995/219-03.24.95〕〔http://www.aidsinfobbs.org/periodicals/search/24.txt〕 on more than 50 phase II-IV HIV-1 clinical studies providing consistent, reliable data leading to FDA approval of lamivudine, indinavir, ritonavir and saquinavir. Dr. Berry was also the host of (MedTalk ) and HearTalk radio talk show. ==References== 〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Paul S. Berry」の詳細全文を読む スポンサード リンク
|